Last reviewed · How we verify
Fentanyl sublingual spray
At a glance
| Generic name | Fentanyl sublingual spray |
|---|---|
| Also known as | Abstral, Fentanyl SL Spray, FSS, SUBSYS®, SUBSYS |
| Sponsor | INSYS Therapeutics Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sublingual Fentanyl for the Management of Breakthrough Pain (PHASE2)
- Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea (PHASE2, PHASE3)
- Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients (PHASE2)
- Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl (PHASE4)
- Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain (PHASE2)
- Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting (PHASE3)
- Sublingual Fentanyl and Procedural Burn Pain (PHASE3)
- Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl sublingual spray CI brief — competitive landscape report
- Fentanyl sublingual spray updates RSS · CI watch RSS
- INSYS Therapeutics Inc portfolio CI